J. Bale, P. Chee
Infliximab is a high-affinity recombinant chimeric immunoglob- ulin-1 monoclonal antibody directed against tumour necrosis factor-alpha. It is used to treat a range of inflammatory disor- ders including psoriatic joint and skin changes. Acute intersti- tial lung disease is a rare but potentially fatal complication of therapy. We report the case of a 67-year-old man with severe psoriasis who presented with acute alveolitis shortly after his third infusion of infliximab. The infliximab was discontinued and investigations did not reveal an infective cause. His respi- ratory signs and symptoms improved quickly with corticos- teroid therapy. Clinicians should be aware of this uncommon but potentially serious complication.
